Organism: Homo sapiens
Gene: 39142_at
Selected probe(set): 224830_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39142_at (224830_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-3.1550932
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Relative Expression (log2-ratio):2.6840382
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-2.6468363
Number of Samples:3 / 5

Experimental	ovarian tumor study 16
	Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control	normal ovarian surface epithelial cell sample
	Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

Relative Expression (log2-ratio):2.596119
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):2.5452795
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-2.4877014
Number of Samples:8 / 17

Experimental	pediatric septic shock study 3 (infant; subclass A)
	Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control	normal blood sample (infant)
	Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

Relative Expression (log2-ratio):2.3835497
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.3259563
Number of Samples:2 / 2

Experimental	collecting duct carcinoma study 1
	Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control	normal kidney tissue (fetal)
	Normal fetal kidney tissue samples.

Relative Expression (log2-ratio):2.3207226
Number of Samples:8 / 231

Experimental	Huntington's disease study 16 (batch L)
	Blood samples obtained from Huntington´s disease patients (batch L).
Control	control blood sample
	Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.

Relative Expression (log2-ratio):2.2726002
Number of Samples:8 / 205

Experimental	Huntington's disease study 16 (batch L)
	Blood samples obtained from Huntington´s disease patients (batch L).
Control	Parkinson's disease study 32 (IPD)
	Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.